Paulette Denise Chandler, M.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Cholecalciferol | 6 | 2021 | 557 | 1.210 |
Why?
|
| Vitamin D | 6 | 2018 | 3311 | 1.140 |
Why?
|
| Vitamins | 5 | 2020 | 1638 | 0.980 |
Why?
|
| Vitamin D Deficiency | 6 | 2020 | 1389 | 0.910 |
Why?
|
| Dietary Supplements | 9 | 2021 | 3445 | 0.680 |
Why?
|
| Vitamin D-Binding Protein | 1 | 2018 | 130 | 0.550 |
Why?
|
| Oxidoreductases Acting on CH-CH Group Donors | 1 | 2018 | 173 | 0.540 |
Why?
|
| Colorectal Neoplasms | 6 | 2022 | 6979 | 0.510 |
Why?
|
| Hydrochlorothiazide | 1 | 2014 | 95 | 0.450 |
Why?
|
| Minority Groups | 1 | 2021 | 1215 | 0.450 |
Why?
|
| C-Peptide | 1 | 2015 | 444 | 0.430 |
Why?
|
| Polysaccharides | 2 | 2016 | 1024 | 0.420 |
Why?
|
| Kallikreins | 1 | 2014 | 221 | 0.420 |
Why?
|
| Neoplasms | 9 | 2021 | 22389 | 0.410 |
Why?
|
| Women's Health | 4 | 2018 | 2079 | 0.410 |
Why?
|
| Inflammation Mediators | 3 | 2018 | 1892 | 0.400 |
Why?
|
| Glycoproteins | 2 | 2016 | 2207 | 0.390 |
Why?
|
| Hypercalcemia | 1 | 2014 | 423 | 0.370 |
Why?
|
| Adiponectin | 2 | 2018 | 1118 | 0.350 |
Why?
|
| Neoplasm Metastasis | 1 | 2020 | 4931 | 0.340 |
Why?
|
| Appendiceal Neoplasms | 1 | 2020 | 155 | 0.300 |
Why?
|
| Adiposity | 2 | 2021 | 1888 | 0.270 |
Why?
|
| Coronary Disease | 1 | 2020 | 5926 | 0.260 |
Why?
|
| Lipids | 2 | 2016 | 3346 | 0.250 |
Why?
|
| Biomedical Research | 1 | 2021 | 3463 | 0.250 |
Why?
|
| Double-Blind Method | 8 | 2021 | 12450 | 0.250 |
Why?
|
| Calcium | 2 | 2015 | 5793 | 0.240 |
Why?
|
| Inflammation | 5 | 2019 | 10863 | 0.240 |
Why?
|
| Prostate-Specific Antigen | 1 | 2014 | 2483 | 0.230 |
Why?
|
| Hypertension | 2 | 2021 | 8610 | 0.210 |
Why?
|
| Middle Aged | 24 | 2021 | 223406 | 0.200 |
Why?
|
| Plants, Edible | 1 | 2021 | 30 | 0.190 |
Why?
|
| Fats | 1 | 2020 | 99 | 0.170 |
Why?
|
| Polymorphism, Single Nucleotide | 2 | 2022 | 16023 | 0.160 |
Why?
|
| Risk Factors | 11 | 2022 | 74915 | 0.160 |
Why?
|
| Obesity | 6 | 2021 | 13065 | 0.160 |
Why?
|
| Acute-Phase Proteins | 2 | 2016 | 251 | 0.160 |
Why?
|
| Feeding Behavior | 2 | 2021 | 3202 | 0.150 |
Why?
|
| Amino Acids, Branched-Chain | 1 | 2020 | 269 | 0.150 |
Why?
|
| Proportional Hazards Models | 4 | 2020 | 12561 | 0.140 |
Why?
|
| Female | 23 | 2024 | 396926 | 0.140 |
Why?
|
| Diet Surveys | 1 | 2021 | 1161 | 0.140 |
Why?
|
| Randomized Controlled Trials as Topic | 4 | 2018 | 10358 | 0.130 |
Why?
|
| Acetylgalactosamine | 1 | 2016 | 41 | 0.130 |
Why?
|
| Aged | 15 | 2021 | 171514 | 0.130 |
Why?
|
| Apolipoprotein B-100 | 1 | 2016 | 157 | 0.130 |
Why?
|
| Vegetables | 1 | 2020 | 1202 | 0.120 |
Why?
|
| United States | 10 | 2024 | 73120 | 0.120 |
Why?
|
| Humans | 32 | 2024 | 768369 | 0.120 |
Why?
|
| Apolipoprotein A-I | 1 | 2016 | 305 | 0.120 |
Why?
|
| Acetylglucosamine | 1 | 2016 | 189 | 0.120 |
Why?
|
| Odds Ratio | 2 | 2018 | 9687 | 0.110 |
Why?
|
| Incidence | 3 | 2018 | 21552 | 0.110 |
Why?
|
| Case-Control Studies | 3 | 2016 | 22286 | 0.110 |
Why?
|
| Metabolomics | 2 | 2022 | 1675 | 0.110 |
Why?
|
| Parathyroid Hormone | 1 | 2020 | 1804 | 0.110 |
Why?
|
| C-Reactive Protein | 4 | 2018 | 3854 | 0.110 |
Why?
|
| Calcifediol | 1 | 2013 | 160 | 0.100 |
Why?
|
| Overweight | 2 | 2021 | 2428 | 0.100 |
Why?
|
| Prospective Studies | 5 | 2018 | 54913 | 0.100 |
Why?
|
| Body Mass Index | 6 | 2021 | 13030 | 0.100 |
Why?
|
| Mendelian Randomization Analysis | 1 | 2018 | 1036 | 0.100 |
Why?
|
| Body Composition | 1 | 2021 | 2455 | 0.090 |
Why?
|
| Follow-Up Studies | 6 | 2022 | 39429 | 0.090 |
Why?
|
| Male | 15 | 2021 | 364761 | 0.090 |
Why?
|
| Diuretics | 1 | 2014 | 612 | 0.090 |
Why?
|
| Gene Frequency | 1 | 2018 | 3615 | 0.090 |
Why?
|
| Obesity, Morbid | 1 | 2021 | 1309 | 0.090 |
Why?
|
| Diet | 2 | 2019 | 8098 | 0.090 |
Why?
|
| Adult | 11 | 2021 | 223528 | 0.080 |
Why?
|
| Breast Neoplasms | 4 | 2024 | 21157 | 0.080 |
Why?
|
| Risk Reduction Behavior | 1 | 2016 | 1120 | 0.080 |
Why?
|
| Survival Rate | 2 | 2020 | 12875 | 0.080 |
Why?
|
| Cholesterol, HDL | 1 | 2016 | 1820 | 0.080 |
Why?
|
| Placebos | 1 | 2013 | 1668 | 0.080 |
Why?
|
| Oxidative Stress | 1 | 2020 | 3145 | 0.080 |
Why?
|
| Postmenopause | 1 | 2018 | 2519 | 0.080 |
Why?
|
| Prevalence | 3 | 2021 | 15879 | 0.080 |
Why?
|
| Dose-Response Relationship, Drug | 3 | 2020 | 10784 | 0.080 |
Why?
|
| Triglycerides | 1 | 2016 | 2465 | 0.080 |
Why?
|
| Renal Insufficiency, Chronic | 1 | 2022 | 2291 | 0.070 |
Why?
|
| Linear Models | 1 | 2018 | 5880 | 0.070 |
Why?
|
| Mitochondria | 1 | 2020 | 3672 | 0.070 |
Why?
|
| Bone Density Conservation Agents | 1 | 2014 | 797 | 0.070 |
Why?
|
| Cholesterol, LDL | 1 | 2016 | 2396 | 0.070 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2021 | 4049 | 0.070 |
Why?
|
| Palliative Care | 1 | 2021 | 3644 | 0.060 |
Why?
|
| Primary Health Care | 1 | 2022 | 4736 | 0.060 |
Why?
|
| Comorbidity | 1 | 2020 | 10601 | 0.060 |
Why?
|
| Logistic Models | 2 | 2022 | 13323 | 0.060 |
Why?
|
| Prognosis | 2 | 2016 | 30031 | 0.060 |
Why?
|
| Cross-Sectional Studies | 3 | 2021 | 26348 | 0.060 |
Why?
|
| Body Weight | 1 | 2015 | 4630 | 0.060 |
Why?
|
| Mortality | 1 | 2016 | 2917 | 0.060 |
Why?
|
| Drug Therapy, Combination | 1 | 2014 | 6320 | 0.060 |
Why?
|
| Disease Progression | 1 | 2020 | 13643 | 0.050 |
Why?
|
| Cardiovascular Diseases | 4 | 2021 | 15638 | 0.050 |
Why?
|
| Poultry | 1 | 2022 | 80 | 0.050 |
Why?
|
| Diet, Vegetarian | 1 | 2022 | 181 | 0.040 |
Why?
|
| Young Adult | 3 | 2021 | 60038 | 0.040 |
Why?
|
| Genetic Predisposition to Disease | 2 | 2022 | 18047 | 0.040 |
Why?
|
| Neoplasm Staging | 1 | 2015 | 11249 | 0.040 |
Why?
|
| Phenotype | 1 | 2018 | 16712 | 0.040 |
Why?
|
| Leucine | 1 | 2020 | 549 | 0.040 |
Why?
|
| Cohort Studies | 3 | 2021 | 41782 | 0.040 |
Why?
|
| Adolescent | 3 | 2021 | 89163 | 0.040 |
Why?
|
| Age Factors | 2 | 2020 | 18477 | 0.040 |
Why?
|
| Chromatography, Liquid | 1 | 2022 | 998 | 0.040 |
Why?
|
| Time Factors | 2 | 2020 | 40271 | 0.040 |
Why?
|
| Nigeria | 1 | 2020 | 777 | 0.040 |
Why?
|
| Blood Pressure | 1 | 2013 | 8537 | 0.040 |
Why?
|
| Receptors, Tumor Necrosis Factor, Type I | 1 | 2018 | 257 | 0.040 |
Why?
|
| Receptors, Tumor Necrosis Factor, Type II | 1 | 2018 | 348 | 0.030 |
Why?
|
| Nutrition Assessment | 1 | 2019 | 740 | 0.030 |
Why?
|
| Tandem Mass Spectrometry | 1 | 2022 | 1197 | 0.030 |
Why?
|
| SEER Program | 1 | 2020 | 1476 | 0.030 |
Why?
|
| Chronic Disease | 2 | 2021 | 9379 | 0.030 |
Why?
|
| Fibrinogen | 1 | 2018 | 893 | 0.030 |
Why?
|
| Health Education | 1 | 2021 | 1059 | 0.030 |
Why?
|
| Intercellular Adhesion Molecule-1 | 1 | 2018 | 1133 | 0.030 |
Why?
|
| Multifactorial Inheritance | 1 | 2022 | 1421 | 0.030 |
Why?
|
| Receptor, erbB-2 | 1 | 2024 | 2586 | 0.030 |
Why?
|
| Nuclear Magnetic Resonance, Biomolecular | 1 | 2016 | 510 | 0.030 |
Why?
|
| Lost to Follow-Up | 1 | 2013 | 123 | 0.030 |
Why?
|
| Health Status Disparities | 1 | 2024 | 1876 | 0.030 |
Why?
|
| Intention to Treat Analysis | 1 | 2013 | 417 | 0.030 |
Why?
|
| Fatty Acids, Omega-3 | 1 | 2021 | 1398 | 0.020 |
Why?
|
| Patient Dropouts | 1 | 2013 | 411 | 0.020 |
Why?
|
| Lung Neoplasms | 1 | 2016 | 13589 | 0.020 |
Why?
|
| Celiac Plexus | 1 | 1990 | 34 | 0.020 |
Why?
|
| Blood Proteins | 1 | 2016 | 1183 | 0.020 |
Why?
|
| Neoplasm Invasiveness | 1 | 2018 | 3637 | 0.020 |
Why?
|
| Interleukin-6 | 1 | 2018 | 3234 | 0.020 |
Why?
|
| Bone Density | 1 | 2021 | 3561 | 0.020 |
Why?
|
| Seasons | 1 | 2013 | 1526 | 0.020 |
Why?
|
| Genotype | 1 | 2022 | 13045 | 0.020 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2018 | 4362 | 0.020 |
Why?
|
| Insulin Resistance | 1 | 2020 | 3974 | 0.020 |
Why?
|
| Health Behavior | 1 | 2018 | 2649 | 0.020 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2016 | 6537 | 0.020 |
Why?
|
| Cause of Death | 1 | 2016 | 3727 | 0.020 |
Why?
|
| Administration, Oral | 1 | 2013 | 4040 | 0.020 |
Why?
|
| Multivariate Analysis | 1 | 2018 | 12096 | 0.010 |
Why?
|
| Risk | 1 | 2016 | 9642 | 0.010 |
Why?
|
| Nerve Block | 1 | 1990 | 711 | 0.010 |
Why?
|
| Genome-Wide Association Study | 1 | 2022 | 12771 | 0.010 |
Why?
|
| Pancreatic Neoplasms | 1 | 2020 | 5443 | 0.010 |
Why?
|
| Aged, 80 and over | 2 | 2020 | 59679 | 0.010 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2016 | 3253 | 0.010 |
Why?
|
| Boston | 1 | 2013 | 9359 | 0.010 |
Why?
|
| Algorithms | 1 | 2021 | 14157 | 0.010 |
Why?
|
| Massachusetts | 1 | 2013 | 8905 | 0.010 |
Why?
|
| Retrospective Studies | 2 | 2021 | 81835 | 0.010 |
Why?
|
| Animals | 2 | 2022 | 169424 | 0.010 |
Why?
|
| Carcinoma, Hepatocellular | 1 | 1990 | 2331 | 0.010 |
Why?
|
| Reproducibility of Results | 1 | 2016 | 20232 | 0.010 |
Why?
|
| Pain | 1 | 1990 | 5096 | 0.010 |
Why?
|
| Liver Neoplasms | 1 | 1990 | 4362 | 0.010 |
Why?
|
| Iohexol | 1 | 1990 | 205 | 0.010 |
Why?
|
| Bupivacaine | 1 | 1990 | 412 | 0.000 |
Why?
|
| Treatment Outcome | 1 | 2013 | 65408 | 0.000 |
Why?
|
| Ethanol | 1 | 1990 | 1334 | 0.000 |
Why?
|
| Radiography, Interventional | 1 | 1990 | 1128 | 0.000 |
Why?
|
| Terminal Care | 1 | 1990 | 1773 | 0.000 |
Why?
|
| Child, Preschool | 1 | 1990 | 42620 | 0.000 |
Why?
|
| Tomography, X-Ray Computed | 1 | 1990 | 20763 | 0.000 |
Why?
|